- Research & Development
- About us
- Invest in us
- Malaria & medicines
Delivery of child-friendly antimalarial hits the 100 million mark
One hundred million treatments of Artemether-Lumefantrine Dispersible, an antimalarial developed especially for children with P. falciparum malaria, have been delivered by Novartis to 35 malaria-endemic countries. Artemether-Lumefantrine Dispersible is the product of the partnership between MMV and Novartis. It is the first WHO prequalified child-friendly artemisinin-combination therapy (ACT) and addresses an unmet need for paediatric medicines.
This film, produced by Novartis, accompanies the press release Delivery of child-friendly antimalarial hits the 100 million mark, posted 22 February 2012.